Orionis Biosciences @OrionisBio
Orionis Biosciences Inc. Joined January 2020-
Tweets34
-
Followers138
-
Following8
-
Likes30
Top Alliances Of 2023 - Vote for @OrionisBio / @genentech. Bringing precision drug design to battle cancer and other life threatening diseases 👏invivo.citeline.com/IV148673/In-Vi…
Thank you @tfadell for your support. We’re very excited to have you join the board and help us navigate the future! And a big thank you also to @TwoCentz for having been an incredibly supportive board member over the past years, and for continuing to be part of the journey.…
Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more…
Congratulations to #TBCPartner @OrionisBio who last week announced a partnership with @genentech to leverage its Allo-Glue™ platform for the discovery of small molecule monovalent glues. (1/3)
Great deep-dive on everything @OrionisBio, featuring our CEO Nikolai Kley and @bradloncar for @BiotechTVHQ. Over 20 minutes you'll hear about how our drug discovery and design platforms, inspired by powerful biological mechanisms present in nature, can reach undruggable targets…
Very cool to see a second collaboration on Molecular Glue discovery with @OrionisBio, here with @Roche @genentech. Niko and friends are creative scientists, terrific partners at the bench. Proud to see this platform expand its potential impact. orionisbio.com/2023/09/genent…
Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal endpts.com/genentech-gets…
📢 More news from the #VIBspinoff community: @OrionisBio announces collaboration with @genentech to discover and develop molecular glue class medicines. Applications are possible in major disease areas such as #oncology and #neurodegeneration. 👇 vibbio.tech/46cicvS
Today we announced a collaboration with @genentech to discover and develop molecular glue class medicines using our Allo-Glue™ platform. Learn more: orb.ink/2023_AG
Today at 5:15pm ET, CEO Niko Kley, Ph.D., will be sharing a presentation on our use of modified #cytokines to target immune receptors for selective responses to cancer at @HansonWade’s Annual Induced Proximity-Based Drug Discovery Summit. Learn more: bit.ly/3OgTtQX
CEO Niko Kley, Ph.D., will present on “Using Modified #Cytokines to Target Immune Receptors for Selective Response Towards Cancer” at @HansonWade’s Annual Induced Proximity-Based Drug Discovery Summit next Wednesday at 5:15pm ET in Boston, MA. Learn more: bit.ly/3OgTtQX
Thursday at 9am ET, our CEO Niko Kley will present on the reprogramming of the cancer immunity cycle with cis-acting cytokines at @HansonWade’s Cytokine-Based Drug Development Summit in Boston, MA. Learn more: bit.ly/3OWMNbi #cytokines #cancerresearch #drugdevelopment
Orionis CEO Niko Kley will be presenting at @HansonWade’s 4th Annual Cytokine-Based Drug Development Summit in Boston, MA next week. His presentation will cover the reprogramming of the cancer immunity cycle with cis-acting cytokines. Learn more: bit.ly/3OWMNbi
More fireworks after 6 pm at #AACR23: #CICR townhall with 3 awesome talks about molecular glue degraders. Michael Rapé (@RapeLab), Riccardo Sabatini (@OrionisBio) & Mary Matyskiela (@neomorphinc). Chaired by Ben Ebert (@DFCI_ChemBio). Glueing everybody to their seats. @AACR #TPD
Today we shared preclinical data from our interferon and IL-2 targeted cytokine immunotherapies for cancer at #PEGSEurope Protein & Antibody Engineering Summit showing potent single-agent anti-tumor activity in preclinical models. More here: orb.ink/pegs1122 #PEGSEurope
We are happy to see the news of our latest financing round in the @WSJ following our official announcement yesterday. Check out the full article here to learn more about our team and platforms wsj.com/articles/biote… #immunotherapy #cancerresearch
Lawerence Bly @LawerenceBly
494 Followers 1K Following
AYDIN KIRAN @japandomehouse
4 Followers 32 Following
Jaimiedc @jaimiedc58627
0 Followers 1 Following
Hélène Lebougault @helene83110
60 Followers 3K Following
Carol Magalhães @healthycarioca
108 Followers 899 Following Investor @BBGVentures | prior @GoldmanSachs | @TheCouncilCap @SomosVC_ 🌶️ 🏃🏽♀️🚴🏽♀️🧘🏽♀️health is wealth✨
lionet @lionet10620335
0 Followers 14 Following
dindiok solomon @dindioksolomon2
34 Followers 302 Following
Armand 🏡 @armandcognetta
859 Followers 3K Following Now: making drugs with superpowers @proxbio, mentor @beondeck (ODLB), advisor @menten_ai Past: @Alnylam, @scrippsresearch, @InzenTx, @ycombinator W20
Roman @abrkatabr
13 Followers 48 Following
Christian Sterner @Sterner
1K Followers 739 Following Family man. Friend. Video librarian. Co-founder, @WellcomeMat. Go Buffs 🦬!!!
Fefo (J.A.Alguacil) @ciberfefo
5K Followers 1K Following Comunicación estratégica en @ilusionlabs y tengo un canal de YouTube donde hablo de ello: https://t.co/CRp1gATwR5
Jana Carey Lombardi @LombdiJa36868
4 Followers 94 Following
rakesh sethi @asterixnet
834 Followers 4K Following 75 percent dark energy, 23 percent dark matter rest undecided, seeker of truth, bhakti yogik, wide receiver of info
George Dzaganishvili @GeorgeDzzz
47 Followers 390 Following
Dhaval Shroff @dhaval_shroff
5K Followers 637 Following Autopilot AI @tesla | My trained networks drive the car better than my biological network does
Rahul Rana @rrana03_
6K Followers 1K Following https://t.co/79bAJbQu9u / Investor, SALT Fund @SALTConference / Writer @NotBoringCo + Author, Making Moonshots / prev @Lux_Capital + @GeneralAtlantic + @ArcadiaScience
Marcela Espinosa Vega @marespivega
206 Followers 1K Following
Ten Bridge Communicat.. @TenBridge
922 Followers 902 Following We guide biotech through the big moments.
Jessica Miciak @JessicaMiciak
10 Followers 396 Following
James @LeroyBrown750
6 Followers 190 Following
M K @MK02318646
0 Followers 4 Following
SyeMD @perseushidden
60 Followers 2K Following . e/acc . decentralize all power . playing at the meeting place of medicine, bits and biology
Marsha Perreault @MarshaPerreault
22 Followers 759 Following
Pallav Sengupta @PallavSengupta3
264 Followers 3K Following Fancies as a sommelier! Ardently edits dotfiles! Vim purist. A religious atheist. Simulates biomolecules for a living. Tweets in personal capacity.
Simon Krols @KrolsSimon
118 Followers 266 Following PhD researcher Medicinal Chemistry @ Ghent University working on the development of PROTAC-based therapeutics and nucleosides.
Michael Ahrweiler @MAhrwie
249 Followers 2K Following interested in drug development and intelligent discussions
Zmitter. @pruchkouski
18 Followers 2K Following
Caleb Heaslip @CalebHeaslip
58 Followers 431 Following
Mark @markmullikin
82 Followers 1K Following
Michael Steinbaugh @mjsteinbaugh
1K Followers 4K Following
Michael Schotsaert @mschotsaert
1K Followers 2K Following I study the little things in life, like viruses, immune cells and my two daughters growing up in NYC. I ferment napa cabbage and wort. Assist. prof. @ISMMS
ye Jo @Joye555795
0 Followers 3 Following
Ruben Christiaen @Christiaen_r
34 Followers 41 Following
Nicolas Chanut @ChanutNicolas
229 Followers 1K Following Postdoc at MIT in Roland Pellenq’s group. Interested in adsorption and transport in porous materials (MOFs, shales, cement,...) and many other things.
Sergio Lavilla-Alonso.. @LavillaAlonso
42 Followers 238 Following Scientific Program Leader @ Almirall. Immunology Researcher fighting Dermatology diseases. Team-player. Book reader. Eurovision fan. Airport regular (He/Him)
Avidity Science - Fra.. @AvidityFrance
22 Followers 162 Following Fournisseur de systèmes d'abreuvement pour animaux dans le secteur biomédical et d'unités de purification d'eau pour les laboratoires
Pratik Pandey @Patrick_3pa
84 Followers 978 Following
Ward Capoen @capoenie
281 Followers 288 Following Partner @ V-Bio Ventures, Molecular Biologist, Biotech nerd, recovering Boston-addict, LCHF fan
Tony Fadell @tfadell
209K Followers 487 Following iPod, iPhone, Nest, Investor & NY Times bestselling Author #BUILD
BiotechTV @BiotechTVHQ
6K Followers 34 Following News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
Anje Cauwels @AnjeDolfijn
224 Followers 345 Following Scientist - Biotechnologist - Runner - Mom, with 5 home towns: Brugge, Gent, NYC, Basel, Merelbeke :)
The Wall Street Journ.. @WSJ
20.6M Followers 1K Following Sign up for our newsletters and alerts: https://t.co/QevH0DLisA | Got a tip? https://t.co/iXIigdOLPr | For WSJ customer support: https://t.co/DZgH9n4vAI
Dr. Sanjay Gupta @drsanjaygupta
2.4M Followers 362 Following Associate Professor of Neurosurgery, Emory University Hospital; CNN Chief Medical Correspondent
Andrew Littlehale @AJLLLC
5 Followers 49 FollowingTop Alliances Of 2023 - Vote for @OrionisBio / @genentech. Bringing precision drug design to battle cancer and other life threatening diseases 👏invivo.citeline.com/IV148673/In-Vi…
Going after cancer and combatting undruggable diseases @OrionisBio is evolving immunotherapies that will ultimately help so many! I am proud to be a part of this incredible company. Looking forward to supporting the journey. Today is a great milestone and many more to come 👏
Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more…
First patient dosed AND the legendary Tony Fadell is joining the Board (inventor of the iPod, co-inventor of the iPhone, founder of Nest, etc.) Huge wins! orionisbio.com/2023/11/orioni…
Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more…
Big News! Exciting News! Again😊Very proud to be part of this now, in the past, and in the future! #immunotherapy #cancerresearch
Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more…
#portfolionews Orionis joins the ranks of clinical stage company ... and one of my idols @tfadell joins the board of directors.
Two important company announcements today! 1: First cancer patient dosed in a Phase 1 immunotherapy clinical trial of ORB-011, a first-in-class targeted interferon A-Kine®. 2: @tfadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more…
Congratulations to #TBCPartner @OrionisBio who last week announced a partnership with @genentech to leverage its Allo-Glue™ platform for the discovery of small molecule monovalent glues. (1/3)
Very cool to see a second collaboration on Molecular Glue discovery with @OrionisBio, here with @Roche @genentech. Niko and friends are creative scientists, terrific partners at the bench. Proud to see this platform expand its potential impact. orionisbio.com/2023/09/genent…
📢 More news from the #VIBspinoff community: @OrionisBio announces collaboration with @genentech to discover and develop molecular glue class medicines. Applications are possible in major disease areas such as #oncology and #neurodegeneration. 👇 vibbio.tech/46cicvS
#AACR23 was really inspirational - seeing how quickly fundamental science is moving into the clinic to help patients. Glad to listen to so many exciting talks!!!
More fireworks after 6 pm at #AACR23: #CICR townhall with 3 awesome talks about molecular glue degraders. Michael Rapé (@RapeLab), Riccardo Sabatini (@OrionisBio) & Mary Matyskiela (@neomorphinc). Chaired by Ben Ebert (@DFCI_ChemBio). Glueing everybody to their seats. @AACR #TPD
More fireworks after 6 pm at #AACR23: #CICR townhall with 3 awesome talks about molecular glue degraders. Michael Rapé (@RapeLab), Riccardo Sabatini (@OrionisBio) & Mary Matyskiela (@neomorphinc). Chaired by Ben Ebert (@DFCI_ChemBio). Glueing everybody to their seats. @AACR #TPD
@rikisabatini @MarcHodosh @drsanjaygupta @CNN @OrionisBio Fantastic talk; I loved it!
Novartis-partnered Orionis secures $55M to push cytokine program into clinic - More like this Pharm2Market.app | @OrionisBio @Novartis#immunotherapy #Financing #SeriesC #Research #Pipeline #immunoOncology #MolecularGlues #cytokine #Biotech endpts.com/novartis-partn…
Novartis-partnered Orionis secures $55M to push cytokine program into clinic - More like this Pharm2Market.app | @OrionisBio @Novartis#immunotherapy #Financing #SeriesC #Research #Pipeline #immunoOncology #MolecularGlues #cytokine #Biotech endpts.com/novartis-partn…
🎇 Kudos to @OrionisBio for closing a $55million capital round to expand R&D activities. As a #VIBspin-off, Orionis is leading the way in harnessing cytokines in the fight against cancer and other diseases. Looking forward to clinical trials! 👉 bit.ly/3ePbC9r
@OrionisBio To learn more about our unique approach to cancer immunotherapy and protein degradation, click on this link to watch our Chief Data Scientist Riccardo Sabatini explain! He also outlines the history of cancer and immunotherapy 2/2 x.com/rikisabatini/s…
Very exciting news today from @OrionisBio! So proud to be part of this exciting progress. 1/2
Today we announced exciting updates, including a $55M financing to support our entry into the clinic. Additionally, cancer #immunotherapy pioneer Dr. Robert Petit joined as Head of Clinical Development and Bihua Chen is the newest member of our BOD. orb.ink/pr1022
Today we announced exciting updates, including a $55M financing to support our entry into the clinic. Additionally, cancer #immunotherapy pioneer Dr. Robert Petit joined as Head of Clinical Development and Bihua Chen is the newest member of our BOD. orb.ink/pr1022
Only Riccardo can present the @OrionisBio technology with such flair. Nice primer on one of our portfolio companies. edition.cnn.com/videos/health/…
Trends for United States
You might like
